News
Latest news and updates from Sathgen Therapeutics
December 2023
SiliconIndia magazine recognized us as the one of the ‘10 Most Promising Drug Discovery & Development Companies – 2023‘.
Read more about how we are “Fusing Nature & Science for Breakthrough Anti-Cancer Solutions” at link.
October 2023
We have presented our latest work on clinical development of our anti-cancer and anti-viral molecules at the Pharma Partnering Summit on October 19-20, 2023 at Boston, MA.
August 2023
May 2023
We showcased our work on the anti-cancer drugs at the Pharma Partnering Summit in San Diego, CA, USA, a conference that brings together the pharmaceutical and biotech worlds.
April 2023
The healthy volunteer trial entitled “A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers” was initiated in April 2023.
January 2023
Our first-in-human patient trial entitled “A Single Ascending Dose, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetic Profile of MSP008-22 in Patients with Advanced Solid Tumors” was initiated in January 2023.
December 2017
Patent for MSP008-22 anti-cancer compound granted in USA and Japan.
June 2011
Patent for Synthesis of Cleistanthin A and its derivatives thereof granted in India, USA, Germany, Netherlands, France,
UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.
February 2009
Patent for Process for Synthesis of Cleistanthin granted in India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa.